David Shaw’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

David Shaw’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,871	Closed	-$70K	–	5907
2022 Q1	$70K	Buy	+1,871	New	+$64.7K	﹤0.01%	5064
2021 Q4	–	Sell	-2,240	Closed	-$162K	–	5794
2021 Q3	$162K	Sell	2,240 -659	-23%	-$50.4K	﹤0.01%	4619
2021 Q2	$278K	Sell	2,899 -1,913	-40%	-$211K	﹤0.01%	4316
2021 Q1	$711K	Buy	4,812 +2,754	+134%	+$499K	﹤0.01%	3329
2020 Q4	$288K	Buy	+2,058	New	+$333K	﹤0.01%	3615
2016 Q2	–	Sell	-130	Closed	-$167K	–	3584
2016 Q1	$167K	Buy	+130	New	+$185K	﹤0.01%	3224

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

David Shaw's NBSE Position: Q2 2022 in Review

David Shaw sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2022, closing a stake of 1,871 shares — an estimated $70K sold.

David Shaw first reported a position in NBSE in Q1 2016 and held it in 6 quarters. The position peaked at $711K in Q1 2021. 43 funds tracked by Wall St. Rank hold NBSE as of Q2 2022.

David Shaw reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
David Shaw sold 1,871 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $70K.
David Shaw first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2016 and held it in 6 quarters.
David Shaw's NeuBase Therapeutics, Inc. Common Stock position peaked at $711K in Q1 2021.
43 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.